Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Camidanlumab Tesirine
Synonyms
Therapy Description

Camidanlumab Tesirine (ADCT-301) is a human nomoclonal antibody against CD25 in conjugation with pyrrolobenzodiazepine dimer toxin, which may specifically target CD25-positive tumor cells (Blood 2017 130(Suppl 1):1510, PMID: 32521310, PMID: 32912922).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Camidanlumab Tesirine ADCT-301|ADCT 301|ADCT301 Camidanlumab Tesirine (ADCT-301) is a human nomoclonal antibody against CD25 in conjugation with pyrrolobenzodiazepine dimer toxin, which may specifically target CD25-positive tumor cells (Blood 2017 130(Suppl 1):1510, PMID: 32521310, PMID: 32912922).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04639024 Phase II Camidanlumab Tesirine ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN Recruiting USA 0
NCT03621982 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Terminated USA | BEL 1
NCT04052997 Phase II Camidanlumab Tesirine Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma Terminated USA | ITA | FRA | ESP | DEU | CAN | BEL 4
NCT02432235 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma Completed USA 1


Additional content available in CKB BOOST